Imunon Inc (IMNN) - Total Liabilities
Based on the latest financial reports, Imunon Inc (IMNN) has total liabilities worth $4.91 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Imunon Inc (IMNN) cash flow conversion to assess how effectively this company generates cash.
Imunon Inc - Total Liabilities Trend (1996–2024)
This chart illustrates how Imunon Inc's total liabilities have evolved over time, based on quarterly financial data. Check Imunon Inc (IMNN) asset resilience to evaluate the company's liquid asset resilience ratio.
Imunon Inc Competitors by Total Liabilities
The table below lists competitors of Imunon Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Manhattan Corporation Ltd
AU:MHC
|
Australia | AU$147.69K |
|
Nanotech Indonesia Global Tbk PT
JK:NANO
|
Indonesia | Rp42.12 Billion |
|
Adaptimmune Therapeutics Plc
NASDAQ:ADAP
|
USA | $201.59 Million |
|
Great Western Exploration Ltd
AU:GTE
|
Australia | AU$357.40K |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $1.60 Million |
|
Viking Mines Ltd
AU:VKA
|
Australia | AU$370.98K |
|
Bhakti Agung Propertindo
JK:BAPI
|
Indonesia | Rp266.21 Billion |
Liability Composition Analysis (1996–2024)
This chart breaks down Imunon Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of Imunon Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.55 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Imunon Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Imunon Inc (1996–2024)
The table below shows the annual total liabilities of Imunon Inc from 1996 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $5.47 Million | -35.84% |
| 2023-12-31 | $8.53 Million | -41.76% |
| 2022-12-31 | $14.65 Million | -19.74% |
| 2021-12-31 | $18.25 Million | -3.52% |
| 2020-12-31 | $18.92 Million | -20.25% |
| 2019-12-31 | $23.72 Million | -8.75% |
| 2018-12-31 | $25.99 Million | +24.91% |
| 2017-12-31 | $20.81 Million | -13.74% |
| 2016-12-31 | $24.12 Million | -15.78% |
| 2015-12-31 | $28.64 Million | -15.43% |
| 2014-12-31 | $33.87 Million | +139.41% |
| 2013-12-31 | $14.15 Million | +5.60% |
| 2012-12-31 | $13.40 Million | +107.52% |
| 2011-12-31 | $6.46 Million | -9.08% |
| 2010-12-31 | $7.10 Million | +48.88% |
| 2009-12-31 | $4.77 Million | +20.39% |
| 2008-12-31 | $3.96 Million | -52.77% |
| 2007-12-31 | $8.39 Million | -62.10% |
| 2006-12-31 | $22.13 Million | +77.27% |
| 2005-12-31 | $12.48 Million | +145.70% |
| 2004-12-31 | $5.08 Million | +414.88% |
| 2003-12-31 | $986.84K | +27.34% |
| 2002-12-31 | $774.96K | +169.42% |
| 2001-12-31 | $287.64K | -26.51% |
| 2000-12-31 | $391.39K | -34.77% |
| 1999-12-31 | $600.00K | -72.50% |
| 1998-12-31 | $2.18 Million | -33.56% |
| 1997-12-31 | $3.28 Million | +27.99% |
| 1996-12-31 | $2.57 Million | -- |
About Imunon Inc
Imunon, Inc., a clinical-stage biotechnology company, focuses on developing immunotherapies and vaccines. The company's lead clinical program is IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-2… Read more